CHMP recommends Spedra (avanafil) as a treatment for Erectile Dysfunction in adult men
Vivus, the USA-based pharmaceutical company has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending European Commission approval for Spedra (Avanafil) for the treatment of erectile dysfunction in adult men.
Avanafil is a selective phosphodiesterase type 5 inhibitor which increased the percentage of sexual attempts resulting in successful intercourse by roughly 20%-30% over placebo in the general population of adult men with erectile dysfunction during the clinical trials. The most common side effects are headache, flushing, nasal and sinus congestion, dyspepsia and back pain.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins